In addition, pharmacological or genetic promotion of NEDD4L may represent a promising therapeutic strategy for treating ischemic diseases, such as myocardial infarction, which exacerbates diabetic retinopathy and critical limb ischemia, by promoting an angiogenic role in the ischemic tissues [53]. This evidence concerns the gene NEDD4L and myocardial infarction.